RETROSPECTIVE STUDY OF ERLOTINIB IN PREVIOUSLY TREATED NSCLC PATIENTS WITH WILD-TYPE EGFR

被引：0
|
作者：
Nakahara, Yoshiro [1 ]
Hosomi, Yukio [1 ]
Yomota, Makiko [1 ]
Okuma, Yusuke [1 ]
Takagi, Yusuke [1 ]
Iguchi, Mari [1 ]
Okamura, Tatsuru [1 ]
机构：
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 11期
关键词：
wild-type EGFR; Erlotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-034
引用
收藏
页码：S490 / S490
页数：1
相关论文
共 50 条
  • [21] Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study
    Alanen, Virve
    Iivanainen, Sanna
    Arffman, Martti
    Koivunen, Jussi Pekka
    ESMO OPEN, 2020, 5 (05)
  • [22] Prognostic value of CYFRA 21-1 and Ki67 in advanced NSCLC patients with wild-type EGFR
    Li, Tao
    Xie, Qi
    Fang, Yang-Yang
    Sun, Yi
    Wang, Xiao Ming
    Luo, Zhu
    Yan, Gui-Ling
    He, Jian-Bo
    Zheng, Xiao-Qun
    BMC CANCER, 2023, 23 (01)
  • [23] Observational Study on Prolonged Disease Stabilization in Advanced NSCLC EGFR WT/Unknown Patients Treated with Erlotinib in Second Line
    Grossi, Francesco
    Montanino, Agnese
    Migliorino, Maria Rita
    Santo, Antonio
    De Tursi, Michele
    Delmonte, Angelo
    Vitiello, Fabiana
    Mencoboni, Manlio
    D'Alessandro, Vito
    Romano, Giampiero
    Rijavec, Erika
    Misino, Andrea
    Chella, Antonio
    Roselli, Mario
    Cavuto, Silvio
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S675 - S676
  • [24] Clinical and biological significance of erlotinib therapy after pemetrexed in non-small cell lung cancer with wild-type EGFR
    Koyama, N.
    Suzuki, M.
    NEOPLASMA, 2015, 62 (06) : 996 - 1004
  • [25] STUDY OF PHARMACOKINETIC AND PHARMACOGENOMIC CHARACTERISTICS IN PATIENTS WITH ADVANCED NSCLC TREATED WITH ERLOTINIB
    Tiseo, Marcello
    Andreoli, Roberta
    Gelsomino, Francesco
    Mozzoni, Paola
    Azzoni, Cinzia
    Bartolotti, Marco
    Bortesi, Beatrice
    Silini, Enrico Maria
    Mutti, Antonio
    Ardizzoni, Andrea
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1103 - S1104
  • [26] A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
    Wang, Duo
    Zhou, Jun
    Fang, Weimin
    Huang, Cuiqing
    Chen, Zerong
    Fan, Meng
    Zhang, Ming-Rong
    Xiao, Zeyu
    Hu, Kuan
    Luo, Liangping
    BIOACTIVE MATERIALS, 2022, 13 : 312 - 323
  • [27] EGFR MUTATION AND OUTCOMES IN PATIENTS WITH METASTATIC NSCLC TREATED WITH ERLOTINIB AT INSTITUTO ONCOLOGICO NACIONAL. PANAMA
    Castillo-Fernandez, Omar
    Arauz, Erick
    Cabreja, Angela
    Loo, Yong
    Veliz, Ignacio
    Guardia, Mario
    Rodriguez, Ivette
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S189 - S189
  • [28] Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung Cancer
    Minemura, Hiroyuki
    Yokouchi, Hiroshi
    Azuma, Keisuke
    Hirai, Kenichiro
    Sekine, Satoko
    Oshima, Kengo
    Kanazawa, Kenya
    Tanino, Yoshinori
    Inokoshi, Yayoi
    Ishii, Taeko
    Katsuura, Yutaka
    Oishi, Akio
    Ishida, Takashi
    Munakata, Mitsuru
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S547 - S547
  • [29] Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
    Walleser, Silke
    Ray, Joshua
    Bischoff, Helge
    Vergnenegre, Alain
    Rosery, Hubertus
    Chouaid, Christos
    Heigener, David
    de Castro Carpeno, Javier
    Tiseo, Marcello
    Walzer, Stefan
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2012, 4 : 269 - 275
  • [30] The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis
    Wu, Fazong
    Song, Jingjing
    Zhao, Zhongwei
    Huang, Xufang
    Mao, Jianting
    Tu, Jianfei
    Chen, Minjiang
    Chen, Weigian
    Fang, Shiji
    Zheng, Liyun
    Fan, Xiaoxi
    MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2019, 16 (06) : 7921 - 7933
12345